Suzetrigine is a novel, non-opioid analgesic active pharmaceutical ingredient and a selective voltage-gated sodium channel blocker. It was developed by Vertex Pharmaceuticals under the development code VX-548 and is marketed in the United States as JOURNAVX. The U.S. FDA approved suzetrigine in January 2025 for the treatment of moderate to severe acute pain, including postoperative pain, in adults. It represents a first-in-class non-opioid approach to acute pain management.
Suzetrigine has the molecular formula C21H20F5N3O4 and a molecular weight of 473.39 g/mol. PubChem identifies the substance under CAS 2649467-58-1 and development code VX-548.
The chemical name of suzetrigine is 4-[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-amido]pyridine-2-carboxamide. The molecule contains four defined stereocenters, making stereochemical purity an important aspect of pharmaceutical quality control.
Suzetrigine is a small-molecule drug substance rather than an opioid or conventional cyclooxygenase-inhibiting analgesic. Its selective activity at peripheral sodium channels provides a pharmacological approach that directly targets neuronal pain transmission.
Suzetrigine selectively blocks the NaV1.8 voltage-gated sodium channel. NaV1.8 is expressed in peripheral sensory neurons, including dorsal root ganglion neurons, where it participates in transmission of pain-related action potentials. Blocking this channel reduces transmission of pain signals toward the spinal cord and brain.
Suzetrigine also produces an active metabolite, M6-SUZ, which inhibits NaV1.8 but is approximately 3.7-fold less potent than suzetrigine in the cited electrophysiological assay.
The principal established pharmaceutical application of suzetrigine is the treatment of moderate to severe acute pain in adults, including postoperative pain. The current U.S. product is supplied as 50 mg oral tablets.
The FDA-approved starting dose is 100 mg, followed 12 hours later by 50 mg every 12 hours. The product is intended for short-term acute-pain treatment rather than chronic opioid replacement in all pain conditions.
Suzetrigine is described by FDA as a white to off-white solid and is practically insoluble in water. FDA's drug-substance assessment found very low aqueous solubility across the tested pH range. At room temperature, solubility was not detected in water and was classified as practically insoluble in the tested aqueous media.
In the FDA assessment, suzetrigine was classified as a BCS Class II drug substance because of low solubility and high permeability. Organic-solvent testing showed substantially greater solubility in acetone and tetrahydrofuran than in aqueous media.
Quality control of Suzetrigine API requires control of identity, assay, organic impurities, degradation products, residual solvents, water content and stereochemical purity. Because suzetrigine contains defined stereochemistry, appropriate chiral analytical procedures are particularly relevant for controlling the corresponding enantiomeric impurity.
The FDA's CMC review states that the proposed drug-substance impurity specifications were acceptable and that potentially significant organic impurities were evaluated for safety qualification.
A recent analytical study also demonstrates the use of chiral HPLC for determination of suzetrigine and its R-enantiomer, highlighting the importance of enantiomeric purity in quality control.
Suzetrigine is a chemically synthesized small molecule requiring control of stereochemical integrity and process-related impurities throughout manufacturing. Pharmaceutical-grade production should employ validated synthetic processes, controlled starting materials, appropriate in-process testing and validated analytical methods.
The final drug substance should be evaluated against its registered specification before release for pharmaceutical manufacturing.
Suzetrigine API should be packaged in suitable pharmaceutical-grade, well-closed containers that protect the material from moisture, contamination and other environmental factors. Storage conditions should follow validated stability data and the applicable registered API specification.
For the finished JOURNAVX product, FDA labeling specifies storage at 20–25°C, with permitted excursions between 15–30°C. This finished-product condition should not automatically be treated as the API storage specification.
A pharmaceutical Suzetrigine API manufacturer should be able to provide appropriate quality and regulatory documentation, such as a Certificate of Analysis, specification sheet, analytical methods, safety documentation, batch information and supporting regulatory documentation as applicable.
A qualified Suzetrigine API manufacturer in India should maintain stringent controls over stereochemical purity, assay, related substances, residual solvents and other critical quality attributes. As a relatively new non-opioid analgesic API, consistent process control and analytical characterization are particularly important for maintaining batch-to-batch quality.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |